Page 1 | Search Results | Blood | American Society of Hematology

1-20 of 27

Sort by

Sort Order Select

Journal Articles

Real-World Effectiveness of Tafasitamab (Tafa) for the Treatment of Relapsed/Refractory Diffuse Large B-Cell Lymphoma (R/R DLBCL) in the United States

Kimberly Saverno, Loretta Nastoupil, Bruce Feinberg, John Galvin, Prathamesh Pathak, Theresa Amoloja, Danielle Gentile, Parisa Asgarisabet, Narendranath Epperla

Blood (2024) 144 (Supplement 1): 2375.

https://doi.org/10.1182/blood-2024-193264

Published: 2024

Journal Articles

Real-World Patient Characteristics and Outcomes in Patients with Relapsed or Refractory Multiple Myeloma Receiving Teclistamab across Community Oncology Practices in the US

Blood (2024) 144 (Supplement 1): 7843.

https://doi.org/10.1182/blood-2024-208708

Published: 2024

Journal Articles

Real-World Patient Characteristics and Outcomes in Patients with High-Risk Cytogenetic Relapsed or Refractory Multiple Myeloma Receiving Teclistamab across Community Oncology Practices in the US

Blood (2024) 144 (Supplement 1): 7854.

https://doi.org/10.1182/blood-2024-210841

Published: 2024

Journal Articles

Real-World Patient Characteristics and Treatment Patterns in ALL Survivors with Relapsed/Refractory ALL

Tammy Schuler, Puja Aggarwal, Angele Kotomale, Lindsay McAllister, Andrew Klink, Bruce Feinberg

Blood (2024) 144 (Supplement 1): 5856.

https://doi.org/10.1182/blood-2024-207719

Published: 2024

Journal Articles

Real-World Use of Tafasitamab (tafa) for Relapsed or Refractory (R/R) Diffuse Large B-Cell Lymphoma (DLBCL) Among Racial and Ethnic Minorities in the United States

Narendranath Epperla, Loretta J. Nastoupil, Kristin M. Zimmerman Savill, Bruce Feinberg, John Galvin, Prathamesh Pathak, Sarah Gordon, Theresa Amoloja, Mae Llorente, Kimberly Saverno

Blood (2023) 142 (Supplement 1): 2415.

https://doi.org/10.1182/blood-2023-173456

Published: 2023

Journal Articles

Tafasitamab for the Treatment of Relapsed/Refractory (R/R) Diffuse Large B-Cell Lymphoma (DLBCL) in the US Real-World Setting

Kimberly Saverno, Kristin M. Zimmerman Savill, Bruce Feinberg, John Galvin, Prathamesh Pathak, Sarah Gordon, Theresa Amoloja, Mae Llorente, Narendranath Epperla, Loretta J. Nastoupil

Blood (2023) 142 (Supplement 1): 265.

https://doi.org/10.1182/blood-2023-173143

Published: 2023

Journal Articles

Adoption of Approved CAR-T Therapies Among US Community Hematologists/ Oncologists

Ajeet Gajra, MD MBBS, Skyler Hime, Yolaine Jeune-Smith, PhD, Bruce Feinberg, DO

Blood (2020) 136 (Supplement 1): 34–35.

https://doi.org/10.1182/blood-2020-141990

Published: 2020

Journal Articles

Real-World Adverse Events Associated with Tisagenlecleucel in Acute Lymphoblastic Leukemia and Large B-Cell Lymphoma

Marjorie E Zettler, PhD MPH, Bruce Feinberg, DO, Alexandrina Balanean, Ajeet Gajra, MD MBBS

Blood (2020) 136 (Supplement 1): 12.

https://doi.org/10.1182/blood-2020-142061

Published: 2020

Journal Articles

Assessment of Measurable Residual Disease (MRD) in Chronic Lymphocytic Leukemia (CLL) and Multiple Myeloma (MM) Among U.S. Community Hematologists/ Oncologists (cH/O)

Ajeet Gajra, MD MBBS, Yamini S Rathish, Yolaine Jeune-Smith, PhD, Andrew J Klink, PhD MPH, Bruce Feinberg, DO

Blood (2020) 136 (Supplement 1): 42–43.

https://doi.org/10.1182/blood-2020-142005

Published: 2020

Journal Articles

Age-Based Disparities in Clinical Trials Supporting FDA Approval of Therapies for Hematologic Malignancies

Ajeet Gajra, MD MBBS, Marjorie E Zettler, PhD MPH, Eli G Phillips, Jr., PharmD, JD, Bruce Feinberg, DO

Blood (2020) 136 (Supplement 1): 21–22.

https://doi.org/10.1182/blood-2020-142064

Published: 2020

Journal Articles

Real-World Effectiveness of First-Line (1L) Dasatinib Versus 1L Imatinib in Newly Diagnosed Patients with Chronic Phase Chronic Myeloid Leukemia (CP-CML)

Andrew J Klink, PhD MPH, Scott Justin Keating, MS, John Brokars, MS, Arianna Kee, Ronda Copher, PhD, Brian Stwalley, PharmD BCGP, Bruce Feinberg, DO, Elias Jabbour, MD

Blood (2020) 136 (Supplement 1): 1–2.

https://doi.org/10.1182/blood-2020-141125

Published: 2020

Journal Articles

Acute Myeloid Leukemia/Myelodysplastic Syndrome (AML/MDS) Associated with PARP Inhibitors: A Real-World Analysis

Ajeet Gajra, MD MBBS, Marjorie E Zettler, PhD MPH, Andrew J Klink, PhD MPH, Bruce Feinberg, DO

Blood (2020) 136 (Supplement 1): 19.

https://doi.org/10.1182/blood-2020-142069

Published: 2020

Journal Articles

Utilization of Immune Checkpoint Inhibitors for Relapsed/Refractory Classical Hodgkin Lymphoma (R/R cHL) in Oncology Community Practices

Ajeet Gajra, MD FACP, Andrew J Klink, PhD MPH, Chadi Nabhan, MDMBA, FACP, Bruce Feinberg, DO

Blood (2019) 134 (Supplement_1): 4057.

https://doi.org/10.1182/blood-2019-129632

Published: 2019

Journal Articles

Real-World Utilization of Midostaurin Among Patients with Acute Myeloid Leukemia (AML)

Ajeet Gajra, MD FACP, Andrew J Klink, PhD MPH, Jonathan K. Kish, PhD MPH, Dhruv Chopra, MS, Bruce Feinberg, DO

Blood (2019) 134 (Supplement_1): 5135.

https://doi.org/10.1182/blood-2019-130671

Published: 2019

Journal Articles

Neurological Adverse Events Following CAR-T Cell Therapy: A Real-World Analysis of Adult Patients Treated with Axicabtagene Ciloleucel or Tisagenlecleucel

Ajeet Gajra, MD FACP, Marjorie E Zettler, PhD MPH, Eli G Phillips Jr., PharmD, JD, Andrew J Klink, PhD MPH, Jonathan K. Kish, PhD MPH, Sonam Mehta, Bruce Feinberg, DO

Blood (2019) 134 (Supplement_1): 1952.

https://doi.org/10.1182/blood-2019-129593

Published: 2019

Journal Articles

Adverse Events in Elderly Hodgkin Lymphoma Patients Treated with Pembrolizumab or Nivolumab in the Real World

Marjorie E Zettler, PhD MPH, Chadi Nabhan, MDMBA, FACP, Ajeet Gajra, MD FACP, Bruce Feinberg, DO

Blood (2019) 134 (Supplement_1): 3490.

https://doi.org/10.1182/blood-2019-129553

Published: 2019

Journal Articles

Perceptions of Community Hematologists/Oncologists on the Potential of Data Presented at ASH 2018 and ASCO 2019 to Alter the Standard of Care for Multiple Myeloma Treatment

Ajeet Gajra, MD FACP, Richard Sweat, PhD, Yolaine Jeune-Smith, PhD, Bruce Feinberg, DO

Blood (2019) 134 (Supplement_1): 5822.

https://doi.org/10.1182/blood-2019-129502

Published: 2019

Journal Articles

Real-World Utilization of Midostaurin Among Patients with Systemic Mastocytosis (SM)

Ajeet Gajra, MD FACP, Andrew J Klink, PhD MPH, Dhruv Chopra, MS, Bruce Feinberg, DO

Blood (2019) 134 (Supplement_1): 5378.

https://doi.org/10.1182/blood-2019-131028

Published: 2019

Journal Articles

Treatment Sequence of Lenalidomide (LEN) and Hypomethylating Agents (HMAs) and the Impact on Clinical Outcomes for Patients with Myelodysplastic Syndromes (MDS)

Amer M. Zeidan, MD, Andrew J Klink, PhD MPH, Bruce Feinberg, DO, Michael McGuire, PharmD

Blood (2017) 130 (Supplement 1): 2188.

https://doi.org/10.1182/blood.V130.Suppl_1.2188.2188

Published: 2017

Journal Articles

The Impact of Depression and Use of Anti-Depressants on Healthcare Resource Utilization (HCRU) in Multiple Myeloma (MM) Patients

Jessica Chung, PhD MPH, Damion Nero, PhD, Bruce Feinberg, DO, Jonathan Kish, PhD MPH, Chadi Nabhan, MD MBA, FACP

Blood (2017) 130 (Supplement 1): 3449.

https://doi.org/10.1182/blood.V130.Suppl_1.3449.3449

Published: 2017

NARROW

Real-World Effectiveness of Tafasitamab (Tafa) for the Treatment of Relapsed/Refractory Diffuse Large B-Cell Lymphoma (R/R DLBCL) in the United States

Real-World Patient Characteristics and Outcomes in Patients with Relapsed or Refractory Multiple Myeloma Receiving Teclistamab across Community Oncology Practices in the US

Real-World Patient Characteristics and Outcomes in Patients with High-Risk Cytogenetic Relapsed or Refractory Multiple Myeloma Receiving Teclistamab across Community Oncology Practices in the US

Real-World Patient Characteristics and Treatment Patterns in ALL Survivors with Relapsed/Refractory ALL

Real-World Use of Tafasitamab (tafa) for Relapsed or Refractory (R/R) Diffuse Large B-Cell Lymphoma (DLBCL) Among Racial and Ethnic Minorities in the United States

Tafasitamab for the Treatment of Relapsed/Refractory (R/R) Diffuse Large B-Cell Lymphoma (DLBCL) in the US Real-World Setting

Adoption of Approved CAR-T Therapies Among US Community Hematologists/ Oncologists

Real-World Adverse Events Associated with Tisagenlecleucel in Acute Lymphoblastic Leukemia and Large B-Cell Lymphoma

Assessment of Measurable Residual Disease (MRD) in Chronic Lymphocytic Leukemia (CLL) and Multiple Myeloma (MM) Among U.S. Community Hematologists/ Oncologists (cH/O)

Age-Based Disparities in Clinical Trials Supporting FDA Approval of Therapies for Hematologic Malignancies

Real-World Effectiveness of First-Line (1L) Dasatinib Versus 1L Imatinib in Newly Diagnosed Patients with Chronic Phase Chronic Myeloid Leukemia (CP-CML)

Acute Myeloid Leukemia/Myelodysplastic Syndrome (AML/MDS) Associated with PARP Inhibitors: A Real-World Analysis

Utilization of Immune Checkpoint Inhibitors for Relapsed/Refractory Classical Hodgkin Lymphoma (R/R cHL) in Oncology Community Practices

Real-World Utilization of Midostaurin Among Patients with Acute Myeloid Leukemia (AML)

Neurological Adverse Events Following CAR-T Cell Therapy: A Real-World Analysis of Adult Patients Treated with Axicabtagene Ciloleucel or Tisagenlecleucel

Adverse Events in Elderly Hodgkin Lymphoma Patients Treated with Pembrolizumab or Nivolumab in the Real World

Perceptions of Community Hematologists/Oncologists on the Potential of Data Presented at ASH 2018 and ASCO 2019 to Alter the Standard of Care for Multiple Myeloma Treatment

Real-World Utilization of Midostaurin Among Patients with Systemic Mastocytosis (SM)

Treatment Sequence of Lenalidomide (LEN) and Hypomethylating Agents (HMAs) and the Impact on Clinical Outcomes for Patients with Myelodysplastic Syndromes (MDS)

The Impact of Depression and Use of Anti-Depressants on Healthcare Resource Utilization (HCRU) in Multiple Myeloma (MM) Patients

Email alerts

ASH Publications

American Society of Hematology

Email alerts

ASH Publications

American Society of Hematology

This Feature Is Available To Subscribers Only